key: cord-0826481-3slz56aw authors: Pinney, Sean P.; Giustino, Gennaro; Halperin, Jonathan L.; Mechanick, Jeffrey I.; Neibart, Eric; Olin, Jeffrey W.; Rosenson, Robert S.; Fuster, Valentin title: Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar date: 2020-10-27 journal: J Am Coll Cardiol DOI: 10.1016/j.jacc.2020.08.058 sha: fe1e695ebc4d2ce91cd16e03ade8edd1a59284af doc_id: 826481 cord_uid: 3slz56aw The emergence of a new coronavirus disease (coronavirus disease 2019 [COVID-19]) has raised global concerns regarding the health and safety of a vulnerable population. Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incites a profound inflammatory response leading to tissue injury and organ failure. COVID-19 is characterized by the bidirectional relationship between inflammation and thrombosis. The clinical syndrome is propelled by inflammation producing acute lung injury, large-vessel thrombosis, and in situ microthrombi that may contribute to organ failure. Myocardial injury is common, but true myocarditis is rare. Elderly patients, those with established cardiovascular disease, and mechanically ventilated patients face the highest mortality risk. Therapies for COVID-19 are evolving. The antiviral drug remdesivir, dexamethasone, transfusion of convalescent plasma, and use of antithrombotic therapy are promising. Most require additional prospective studies. Although most patients recover, those who survive severe illness may experience persistent physical and psychological disabilities. . Both asymptomatic and presymptomatic transmission has been described and seems to be a major contributor to viral spread (6) . In a study of asymptomatic infections, the median communicable period was 9.5 days, with a range up to 21 days (7) . Conversely, the outbreak in South Korea was concentrated in the young Shinchenji religious group and contained with early detection and treatment (10) . In Kings County, Washington, 19 of the first 22 deaths were in elderly nursing home patients, but recent analysis now suggests the virus was circulating in the community weeks earlier (11) . Isolation is the most effective method for containing Coronavirus disease (COVID) 2019 produces a spectrum of clinical illness ranging from mild respiratory and constitutional symptoms to pneumonia with severe hypoxia and respiratory failure. Severe illness is associated with systemic inflammation and disturbances in coagulation leading to small-and large-vessel thrombosis. Myocardial injury when present is usually mild but associated with worse outcomes. ALT¼ alanine aminotransferase; AST ¼ aspartate aminotransferase; CRP ¼ C-reactive protein; ESR ¼ erythrocyte sedimentation rate; FiO 2 ¼ fraction of inspired oxygen; IL ¼ interleukin; INR ¼ international normalized ratio; LV ¼ left ventricular; paO 2 ¼ partial pressure of oxygen; SpO 2 ¼ blood oxygen saturation. Pinney et al. IL-6 is a key inflammatory cytokine known to contribute to thrombo-inflammatory responses associated with acute and chronic inflammation (63) . The development of ARDS and microthrombi in the lungs, heart, and kidneys seem to be drivers of fatal disease. There are currently no approved therapies for COVID-19, but remdesivir, convalescent plasma, dexamethasone, and antithrombotic agents seem promising. A novel coronavirus from patients with pneumonia in China 2019 A genomic perspective on the origin and emergence of SARS-CoV Covid-19: epidemiology, evolution, and cross-disciplinary perspectives Defining the epidemiology of Covid-19-studies needed SnapShot: Covid-19 Temporal dynamics in viral shedding and transmissibility of COVID-19 Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing Early transmission dynamics in Wuhan, China of novel coronavirus infectious pneumonia Demographic science aids in understanding the spread and fatality rates of COVID-19 Why are Korea's death rates so low? Available at: https:// bedford.io/blog Cryptic transmission of novel coronavirus revealed by genomic epidemiology. Bedford Lab Blog 2020 Clinical characteristics of coronavirus disease 2019 in China Clinical course and risk factors for mortality of adult inpatients in Wuhan, Chin: a retrospective cohort study Covid-19 in critically ill patients in the Seattle region-case series Clinical characteristics of Covid-19 in New York City Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region Day M. Covid-19 four fifths of cases are asymptomatic China figures indicate Universal screening for SARS-CoV-2 in women admitted for delivery Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection MDA5 and TLR3 initiate pro-inflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to doublestranded RNA and influenza A virus Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3 Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Considerations for statin therapy in patients with COVID-19 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Innate immunity and coagulation Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods The endothelium in acute lung injury/acute respiratory distress syndrome Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury Acute pulmonary embolism and COVID-19 pneumonia: a random association? Endothelial dysfunction is associated with mortality and severity of coagulopathy in patients with sepsis and disseminated intravascular coagulation Coagulopathy and antiphospholipid antibodies in patients with Covid-19 Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China Immune thrombocytopenic purpura in a patient with Covid-19 Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State The variety of cardiovascular presentations of COVID-19 COVID-19-related myocarditis in a 21-year-old female patient Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application Typical takotsubo syndrome triggered by SARS-CoV-2 infection Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study SARS-CoV-2 and viral sepsis: observations and hypotheses Coronavirus disease 2019 (COVID-19) in Italy Centers for Disease Control and Prevention. Provisional death counts for coronavirus disease (COVID-19). Available at Centers for Disease Control and Prevention. Information for clinicians on investigational therapeutics for patients with COVID-19. Available at A randomized, controlled trial of Ebola virus disease therapeutics Remdesivir for the treatment of COVID-19-preliminary report A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Novel role of T cells and IL-6 (interleukin-6) in angiotensin II-induced microvascular dysfunction Off-label use of tocilizumab in patients with SARS-CoV-2 infection Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome The effect of corticosteroid treatment on patients with coronavirus infection: a systemic review and metaanalysis Prevention Treatment of VTE Associated with COVID-19 Infection Consensus Statement Group COVID-19 and VTE/anticoagulation Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-ofthe-Art Review Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19 Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2 Prevention, diagnosis, and treatment of VTE in patients with COVID-19 A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group Extended thromboprophylaxis with betrixaban in acutely ill medical patients Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Observational study of hydroxychloroquine in hospitalized patients with COVID-19 National Institutes of Health. COVID-19 treatment guidelines. Chloroquine or hydroxychloroquine with or without azithromycin Treatment of 5 critically ill patients with COVID-19 convalescent plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients COVID-19: Disease Mechanisms and Clinical Outcomes Persistent symptoms in patients after acute COVID-19 A decade after SARS: strategies for controlling emerging coronaviruses An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection Potential effects of coronaviruses on the cardiovascular system: a review Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors